New Device for Peripheral Nerve Stim Cuts Chronic Low Back Pain

This article originally appeared here.
Share this content:
New Device for Peripheral Nerve Stim Cuts Chronic Low Back Pain
New Device for Peripheral Nerve Stim Cuts Chronic Low Back Pain

MONDAY, March 20, 2017 (HealthDay News) -- A novel method of short-term percutaneous peripheral nerve stimulation (PNS) is useful for producing pain relief and reducing medication use among patients with chronic low back pain (LBP), according to a case report published online March 14 in Pain Practice.

Leonardo Kapural, M.D., Ph.D., from the Center for Clinical Research and Carolina's Pain Institute in Winston Salem, N.C., and colleagues describe the use of PNS in two subjects with chronic LBP. Stimulation was discontinued at the end of the one-month therapy and the leads were withdrawn.

The authors note that PNS produced clinically significant improvements in pain and functional outcomes (62 percent average reduction in Brief Pain Inventory Question #5, average pain; 73 percent reduction in disability, Oswestry Disability Index; 83 percent reduction in pain interference, Brief Pain Inventory). Non-opioid analgesic use was reduced by 83 percent on average, and the subject taking opioids ceased opioid use. Minor skin irritation caused by a topical dressing was the only adverse event. For at least four months after the start of therapy, clinically significant improvements were sustained (79 percent average reduction in pain; both reported minimal disability; and 100 and 74 percent reductions in opioids and non-opioids, respectively).

"This therapy has the potential to shift the paradigm in the management of chronic pain, offering a minimally invasive treatment with the potential to bring the benefits of an effective neuromodulation therapy to patients earlier in the treatment continuum," the authors write.

Several authors disclosed financial ties to SPR Therapeutics, which funded the study. Several authors are listed as inventors on issued or pending patents.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters




More in Home

FDA Approves Palynziq for Phenylketonuria

FDA Approves Palynziq for Phenylketonuria

Drug is a novel enzyme therapy for adult patients with PKU with uncontrolled blood Phe concentrations

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in proportion of adults recommended for treatment; estimated decrease in CVD events, deaths